Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 2 of 53 · 2507 articles
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Personal stories like this show how surgery, nutrition, and tailored exercise can help someone with Crohn’s rebuild strength, body weight, and confidence. They can offer practical ideas and emotional encouragement to...
Long-term risk of needing another intestinal surgery is a major concern for people with Crohn’s disease. This study suggests laparoscopic resection may be linked to lower long-term reoperation risk compared with open...
Early intestinal resection is uncommon but important in pediatric Crohn’s disease. Identifying features linked to surgery soon after diagnosis can help families and clinicians monitor higher-risk children and plan care.
Self-management is central to long-term IBD control. The study shows many patients have limited disease knowledge and less favorable attitudes, which could affect adherence, lifestyle choices, and follow-up.
Postoperative recurrence in Crohn's disease is common and often first detected on endoscopy. If probiotics reduced endoscopic recurrence, it could offer a low-risk, non-pharmacologic strategy to help prevent disease...
Children with Crohn’s disease may have vitamin D deficiency and a theoretical link between vitamin D levels and relapse risk; this trial tested whether adding high‑dose vitamin D3 at diagnosis could lower relapses and...
Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...
Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
The study suggests Crohn’s disease is associated with coordinated brain structure and function differences that relate to disease activity and quality of life, pointing to brain–gut links that could inform future...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
People with Crohn’s disease facing pelvic exenteration or urinary diversion may worry that using ileal tissue is unsafe. This study suggests ileal conduits can be done but carry higher urological complication and...
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
Patients and clinicians may care because the investigational drug duvakitug reportedly sustained clinical and endoscopic benefits through 44 weeks in both ulcerative colitis and Crohn’s disease, which could represent a...
This report documents one‑year outcomes after fecal microbiota transplantation in four very ill children across several indications, including a child with Crohn’s disease and severe C.
Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...
Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.
Cure8 could only read part of this source from communityimpact.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Access, cost, and policy.
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
New Phase 2b maintenance data suggest a novel anti‑TL1A antibody may provide sustained symptom relief and mucosal improvement for some people with moderate-to-severe UC or CD — outcomes that matter because durable...
Early Phase 1b results suggest PALI-2108 may produce rapid improvements on endoscopy and calprotectin in very small Crohn’s and UC cohorts, which could matter if later trials confirm benefit and safety. The findings are...
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over...
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with...
Dietary patterns, especially ultra-processed food intake, are increasingly linked to Crohn's disease activity. This trial could provide randomized evidence on whether reducing ultra-processed foods prolongs remission in...
This trial is testing a novel stem-cell infusion approach aimed at treating Crohn’s disease and ulcerative colitis, so people with IBD may be interested in emerging cell-therapy options and safety data. Phase 1 studies...
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Fistula. Open the original article for the full details.
New Phase 2a data suggest a two‑drug combo from AbbVie may produce higher endoscopic remission than Skyrizi alone, which could matter for future treatment options and for patients who have failed prior advanced...
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
Intestinal fibrosis and strictures are a major unmet need in Crohn’s disease because current anti-inflammatory drugs often don’t reverse established scarring. A drug that limits or reverses fibrosis could reduce the need...
Cure8 found this source from wjgnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Biomarkers, and Biomarker. Open the original article for the full details.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Lipids in Health and Disease.
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that...
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
